Research location
Strasbourg
Bas-Rhin, France
Advertisement
Research activity in Strasbourg
Bas-Rhin, FranceCureCurrent currently publishes aggregate city-level research activity for this location: 42 trials and 45 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Strasbourg
39 linked trials · page 1 of 1Exploring Blood Cell Function and Oxidative Stress to Improve Diagnosis and Treatment in Pre-Capillary Pulmonary HypertensionNCT07176260 · 2025-09-01 · 1 site observation
RECRUITING
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)NCT06925737 · 2025-05-13 · 1 site observation
RECRUITING
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)NCT06353386 · 2024-05-20 · 1 site observation
RECRUITING
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)NCT06136624 · 2023-12-31 · 1 site observation
RECRUITING
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)NCT06136650 · 2023-12-18 · 1 site observation
RECRUITING
Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic ShockNCT04020263 · 2023-07-03 · 1 site observation
RECRUITING
Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority StudyNCT05692999 · 2023-03-20 · 2 site observations
RECRUITING
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in EuropeNCT05363319 · 2022-10-26 · 1 site observation
RECRUITING
Search for Diagnostic and Prognostic Biomarkers in Systemic Sclerosis and Inflammatory MyopathiesNCT04917705 · 2021-11-25 · 1 site observation
RECRUITING
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)NCT07218029 · 2021-05-12 · 1 site observation
RECRUITING
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)NCT04585750 · 2020-10-29 · 1 site observation
RECRUITING
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesNCT04300556 · 2020-08-06 · 1 site observation
RECRUITING
A Study of Mosliciguat in PH-ILDNCT06635850 · 2024-10-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Frequency-time Analysis of Pathological Lung Sounds: Detection and Quantification of Pathological Sounds in Patients With Cystic Fibrosis, Pulmonary Fibrosis or COPD (Chronic Obstructive Pulmonary Disease)NCT06399094 · 2024-07-18 · 1 site observation
TERMINATED
Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)NCT04811092 · 2022-03-18 · 1 site observation
TERMINATED
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)NCT05239728 · 2022-03-15 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)NCT04896008 · 2021-12-01 · 1 site observation
COMPLETED
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)NCT04956692 · 2021-08-05 · 1 site observation
COMPLETED
A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a CatNCT04981717 · 2021-07-30 · 1 site observation
TERMINATED
Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple SclerosisNCT04777539 · 2021-06-14 · 1 site observation
COMPLETED
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)NCT04576988 · 2021-01-25 · 1 site observation
COMPLETED
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)NCT04626479 · 2020-12-16 · 1 site observation
COMPLETED
A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast CancerNCT04385433 · 2020-12-04 · 1 site observation
TERMINATED
A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid ArthritisNCT04497597 · 2020-10-16 · 1 site observation
COMPLETED
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)NCT03834493 · 2019-07-28 · 1 site observation
TERMINATED
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)NCT03867084 · 2019-05-28 · 1 site observation
COMPLETED
Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT03778931 · 2019-05-10 · 1 site observation
COMPLETED
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)NCT03829319 · 2019-03-25 · 1 site observation
COMPLETED
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)NCT03740165 · 2018-12-18 · 1 site observation
COMPLETED
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)NCT03615326 · 2018-10-05 · 1 site observation
COMPLETED
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)NCT03425643 · 2018-04-24 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy of Air Cleaners in Asthmatics Allergic to Cat in ALYATEC Environmental Exposure ChamberNCT03928561 · 2017-12-06 · 1 site observation
COMPLETED
A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate CancerNCT03085095 · 2017-04-18 · 1 site observation
COMPLETED
Observational Study of Obstructive Lung Disease (NOVELTY)NCT02760329 · 2016-07-25 · 1 site observation
COMPLETED
Study of SBRT Efficacy on Intra and Extra -Cranial Tumors or Metastasis in Pediatrics Population (SBRT Pediatrics)NCT02013297 · 2013-12-03 · 1 site observation
COMPLETED
Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019NCT01797965 · 2013-02-15 · 1 site observation
TERMINATED
Study of Geriatric Patients Aged 75 Years or Older Treated and Cured for Localized Prostate Cancer: Case-control StudyNCT01797692 · 2013-01-01 · 1 site observation
COMPLETED
Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple SclerosisNCT01480076 · 2012-02-01 · 1 site observation
COMPLETED
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple SclerosisNCT01058005 · 2010-03-01 · 1 site observation
TERMINATED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.